<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945061</url>
  </required_header>
  <id_info>
    <org_study_id>CASE11107</org_study_id>
    <nct_id>NCT00945061</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Recurrent Breast Cancer</brief_title>
  <official_title>Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill&#xD;
      tumor cells. It is not yet known whether a single dose of radiation therapy is more effective&#xD;
      than implant radiation therapy for 5 days in treating patients with recurrent breast cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying implant radiation therapy to see how well it works&#xD;
      compared with radiation therapy during surgery in treating patients with recurrent breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the in breast recurrence rate following repeat radiation to the breast.&#xD;
           These patients will be followed for a period of five years following completion of&#xD;
           radiation to determine these rates.&#xD;
&#xD;
        -  To determine the cosmetic outcome resulting from partial breast re-irradiation using&#xD;
           different techniques, including both physician and patient rated scales.&#xD;
&#xD;
        -  To determine patient satisfaction of partial breast re-irradiation as it pertains to&#xD;
           their overall treatment experience, as measured by a questionnaire.&#xD;
&#xD;
        -  To determine if there are patient factors illuminated during a discussion of informed&#xD;
           consent, which limit a patient's suitability to receive partial breast re-irradiation&#xD;
           delivered by a particular technique.&#xD;
&#xD;
        -  To evaluate tylectomy wound healing and overall complication rate after partial breast&#xD;
           re-irradiation.&#xD;
&#xD;
        -  To determine ipsilateral breast tumor recurrence rates and tumor bed recurrence&#xD;
           rates.These patients will be followed for a period of five years following completion of&#xD;
           the second course of radiation to determine these rates.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to which modality is best suited for the patient.&#xD;
      Patients are assigned to 1 of 2 groups.&#xD;
&#xD;
      All patients undergo excisional biopsy or needle localization removal of the tumor. Patients&#xD;
      with margins &lt; 2 mm undergo re-excision of the biopsy cavity.&#xD;
&#xD;
        -  Group 1: Patients undergo partial breast irradiation delivered as a single&#xD;
           intra-operative radiation dose to the tumor bed.&#xD;
&#xD;
        -  Group 2: Patients undergo partial breast irradiation delivered by Mammosite®&#xD;
           brachytherapy consisting of 10 fractions over 5 days.&#xD;
&#xD;
      Quality of life is assessed at baseline, 1 month after completion of radiotherapy, and then&#xD;
      at follow-up visits.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 month, every 3 months for&#xD;
      1 year, and then every 6 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2008</start_date>
  <completion_date type="Actual">July 6, 2018</completion_date>
  <primary_completion_date type="Actual">July 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>1 month after radiation therapy (RT)</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>3 months after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>6 months after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>9 months after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>12 months after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>2 years after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>3 years after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>4 years after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence Rates</measure>
    <time_frame>5 years after RT</time_frame>
    <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>1 month after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>3 month after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>6 month after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>12 month after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>2 years after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>3 years after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>4 years after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Bed Recurrence Rates</measure>
    <time_frame>5 years after RT</time_frame>
    <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cosmetic Outcome as Determined by an Established Scale</measure>
    <time_frame>1 month after RT &amp; Q3mos for one year and at 5 years</time_frame>
    <description>Cosmetic outcome as determined by four-level scale of cosmetic outcome scale, with levels poor, fair, good, and excellent in increasingly positive outcomes.&#xD;
Excellent: Minimal or no difference in the size or shape of the treated breast Good: Slight difference in the size or shape of the treated breast Fair: Obvious difference in the shape and size of the treated breast Poor: Obvious difference in the shape and size of the treated breast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>1 month after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>3 month after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>6 month after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>9 month after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>12 month after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>2 years after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>3 years after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>4 years after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</measure>
    <time_frame>5 years after RT</time_frame>
    <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>1 month after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>3 month after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>6 month after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>9 month after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>12 month after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>2 years after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>3 years after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>4 years after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Complications After Intervention</measure>
    <time_frame>5 years after RT</time_frame>
    <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>1 month after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>3 month after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>6 month after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>9 month after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>12 month after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>2 years after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>3 years after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>4 years after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Wound Healing</measure>
    <time_frame>5 years after RT</time_frame>
    <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intraoperative radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracavitary balloon brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intracavitary balloon brachytherapy</intervention_name>
    <description>Patients undergo brachytherapy</description>
    <arm_group_label>Intracavitary balloon brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intraoperative radiation therapy</intervention_name>
    <description>Patients undergo radiotherapy</description>
    <arm_group_label>Intraoperative radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients' recurrences must have histologically confirmed ductal carcinoma in-situ,&#xD;
             invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies.&#xD;
&#xD;
          -  Lesion size ≤ 3 cm treated with a tylectomy and whole breast irradiation (with or&#xD;
             without tumor bed boost)&#xD;
&#xD;
          -  Unifocal breast cancer recurrence&#xD;
&#xD;
          -  Negative resection margins with at least a 2 mm margin from invasive and in situ&#xD;
             cancer or a negative re-excision&#xD;
&#xD;
          -  Hormonal therapy is allowed. If chemotherapy is planned, the radiation is delivered&#xD;
             first and chemotherapy must begin no earlier than two weeks following completion of&#xD;
             radiation.&#xD;
&#xD;
          -  Signed study-specific informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with distant metastatic disease&#xD;
&#xD;
          -  Patients with invasive lobular carcinoma, extensive lobular carcinoma in-situ,&#xD;
             extensive ductal carcinoma in-situ (spanning more than 3 cm), or nonepithelial breast&#xD;
             malignancies such as lymphoma or sarcoma.&#xD;
&#xD;
          -  Patients with multicentric carcinoma (tumors in different quadrants of the breast or&#xD;
             tumors separated by at least 4 cm). Palpable or radiographically suspicious&#xD;
             contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular,&#xD;
             or internal mammary lymph nodes unless these are histologically or cytologically&#xD;
             confirmed negative.&#xD;
&#xD;
          -  Extensive intraductal component (EIC) by the Harvard definition, i.e. 1) more than 25%&#xD;
             of the invasive tumor is Ductal carcinoma in situ (DCIS) and DCIS present in adjacent&#xD;
             breast tissue. Presence of an EIC increases the chance of local recurrence, and as&#xD;
             such, one might not be a candidate for repeat breast conservation.&#xD;
&#xD;
          -  Patients with Paget's disease of the nipple.&#xD;
&#xD;
          -  Patients with skin involvement.&#xD;
&#xD;
          -  Patients with collagen vascular disorders, specifically systemic lupus erythematosis,&#xD;
             scleroderma, or dermatomyositis.&#xD;
&#xD;
          -  Patients with psychiatric, neurologic, or addictive disorders that would preclude&#xD;
             obtaining informed consent.&#xD;
&#xD;
          -  Other malignancy, except non-melanomatous skin cancer, &lt; 5 years prior to&#xD;
             participation in this study.&#xD;
&#xD;
          -  Patients who are pregnant or lactating due to potential fetal exposure to radiation&#xD;
             and unknown effects of radiation on lactating females.&#xD;
&#xD;
          -  Patients with known BReast CAncer gene (BRCA)1/BRCA 2 mutations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Lyons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS Chagrin Highlands Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS Westlake Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <results_first_submitted>July 15, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>invasive ductal breast carcinoma</keyword>
  <keyword>medullary ductal breast carcinoma with lymphocytic infiltrate</keyword>
  <keyword>mucinous ductal breast carcinoma</keyword>
  <keyword>papillary ductal breast carcinoma</keyword>
  <keyword>tubular ductal breast carcinoma</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT00945061/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intraoperative Radiation Therapy</title>
          <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
        </group>
        <group group_id="P2">
          <title>Intracavitary Balloon Brachytherapy</title>
          <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intraoperative Radiation Therapy</title>
          <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
        </group>
        <group group_id="B2">
          <title>Intracavitary Balloon Brachytherapy</title>
          <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>1 month after radiation therapy (RT)</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>3 months after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>6 months after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>9 months after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>12 months after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>2 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>3 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>4 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence Rates</title>
        <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
        <time_frame>5 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence Rates</title>
          <description>Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>1 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>3 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>6 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>12 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>2 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>3 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>4 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Bed Recurrence Rates</title>
        <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
        <time_frame>5 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.&#xD;
Intraoperative radiation therapy: Patients undergo radiotherapy</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.&#xD;
intracavitary balloon brachytherapy: Patients undergo brachytherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Bed Recurrence Rates</title>
          <description>Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cosmetic Outcome as Determined by an Established Scale</title>
        <description>Cosmetic outcome as determined by four-level scale of cosmetic outcome scale, with levels poor, fair, good, and excellent in increasingly positive outcomes.&#xD;
Excellent: Minimal or no difference in the size or shape of the treated breast Good: Slight difference in the size or shape of the treated breast Fair: Obvious difference in the shape and size of the treated breast Poor: Obvious difference in the shape and size of the treated breast</description>
        <time_frame>1 month after RT &amp; Q3mos for one year and at 5 years</time_frame>
        <population>Participants who had data collected for survey. Only participants in group 1 completed survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>1 Month</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O3">
            <title>3 Months</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O4">
            <title>6 Month</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O5">
            <title>9 Months</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O6">
            <title>12 Months</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O7">
            <title>5 Years</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Outcome as Determined by an Established Scale</title>
          <description>Cosmetic outcome as determined by four-level scale of cosmetic outcome scale, with levels poor, fair, good, and excellent in increasingly positive outcomes.&#xD;
Excellent: Minimal or no difference in the size or shape of the treated breast Good: Slight difference in the size or shape of the treated breast Fair: Obvious difference in the shape and size of the treated breast Poor: Obvious difference in the shape and size of the treated breast</description>
          <population>Participants who had data collected for survey. Only participants in group 1 completed survey.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="60"/>
                    <measurement group_id="O7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>1 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>3 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>6 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>9 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>12 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>2 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>3 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>4 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
        <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
        <time_frame>5 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey</title>
          <description>Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey&#xD;
Participants indicate level of satisfaction by answering &quot;my satisfaction about the treatment and results is&quot;&#xD;
I am totally satisfied with the treatment and results&#xD;
I am not totally satisfied but would choose the same treatment again.&#xD;
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.&#xD;
I am dissatisfied with my treatment.</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>1 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>1 month after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>3 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>6 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>9 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>12 month after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>2 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>3 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>4 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Complications After Intervention</title>
        <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
        <time_frame>5 years after RT</time_frame>
        <population>Evaluable participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Complications After Intervention</title>
          <description>Overall complication rate, as measured by percent of participants experiencing complications after intervention</description>
          <population>Evaluable participants enrolled in study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>3 month after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>6 month after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>9 month after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>12 month after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>2 years after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>3 years after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>4 years after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Wound Healing</title>
        <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
        <time_frame>5 years after RT</time_frame>
        <population>Evaluable participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Intraoperative Radiation Therapy</title>
            <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
          </group>
          <group group_id="O2">
            <title>Intracavitary Balloon Brachytherapy</title>
            <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Wound Healing</title>
          <description>Wound healing rate, as measured by percent of participants with delayed wound healing</description>
          <population>Evaluable participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intraoperative Radiation Therapy</title>
          <description>Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.</description>
        </group>
        <group group_id="E2">
          <title>Intracavitary Balloon Brachytherapy</title>
          <description>Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE V3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - nose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphatics: seroma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fibrosis-cosmesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Superficial soft tissue breast fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Dental/teeth/peridontal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Pelvis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast nipple/areolar deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nipple Inversion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Breast indentation/dimpling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin retraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin dimpling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Induration/fibrosis (skin and subcutaneous tissue)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation - Radiation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intra-operative injury - Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Janice A. Lyons, MD</name_or_title>
      <organization>University Hospitals Cleveland Medical Center , Case Comprehensive Cancer Center</organization>
      <phone>+1 216-844-2536</phone>
      <email>Janice.Lyons@uhhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

